Press "Enter" to skip to content

New patent expiration for Mylan Institutional drug ULTIVA


Annual Drug Patent Expirations for ULTIVA
Annual Drug Patent Expirations for ULTIVA

Ultiva is a drug marketed by Mylan Institutional
and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in ULTIVA is remifentanil hydrochloride. One supplier is listed for this compound. Additional details are available on the remifentanil hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
or visit

    Do NOT follow this link or you will be banned from the site!